Human herpesviruses are responsible for a range of debilitating acute and recurrent diseases, including a number of malignancies. Current treatments are limited to targeting the herpesvirus DNA polymerases, but with emerging viral resistance and little efficacy against the oncogenic herpesviruses, there is an urgent need for new antiviral strategies. Here, we describe a mechanism to inhibit the replication of the oncogenic herpesvirus Kaposi's sarcoma-associated herpesvirus (KSHV), by targeting the ATP-dependent formation of viral ribonucleoprotein particles (vRNPs). We demonstrate that small-molecule inhibitors which selectively inhibit the ATPase activity of the cellular human transcription/export complex (hTREX) protein UAP56 result in effective inhibition of vRNP formation, viral lytic replication and infectious virion production. Strikingly, as all human herpesviruses use conserved mRNA processing pathways involving hTREX components, we demonstrate the feasibility of this approach for pan-herpesvirus inhibition. . Like all herpesviruses, KSHV has two distinct forms of infection; latency and lytic replication. Although the majority of KSHV-associated tumorigenic cells harbour latent virus, lytic gene expression occurs to various levels in each KSHV-associated disorder [5] [6] [7] [8] [9] [10] [11] , suggesting that lytic replication inhibition may provide therapeutic intervention. Currently, the drugs in clinical use are inhibitors of herpesvirus DNA polymerases. These nucleotide, nucleoside and pyrophosphate analogues are highly effective against a variety of herpesviruses, although drug-resistant strains can emerge in immunocompromised patients, carrying mutations in genes encoding the thymidine kinase, protein kinase or DNA polymerase 12 . Moreover, varying efficacy has been reported against the oncogenic gamma-herpesvirus subfamily [13] [14] [15] [16] [17] . Consequently, there is an urgent need for the continued development of anti-herpesvirus drugs, particularly targeting oncogenic herpesviruses.
H uman herpesviruses are responsible for a range of acute and chronic diseases, including several cancers [1] [2] [3] . Kaposi's sarcoma-associated herpesvirus (KSHV) is the aetiological agent of Kaposi's sarcoma and two lymphoproliferative disorders: primary effusion lymphoma and multicentric Castleman's disease 4 . Like all herpesviruses, KSHV has two distinct forms of infection; latency and lytic replication. Although the majority of KSHV-associated tumorigenic cells harbour latent virus, lytic gene expression occurs to various levels in each KSHV-associated disorder [5] [6] [7] [8] [9] [10] [11] , suggesting that lytic replication inhibition may provide therapeutic intervention. Currently, the drugs in clinical use are inhibitors of herpesvirus DNA polymerases. These nucleotide, nucleoside and pyrophosphate analogues are highly effective against a variety of herpesviruses, although drug-resistant strains can emerge in immunocompromised patients, carrying mutations in genes encoding the thymidine kinase, protein kinase or DNA polymerase 12 . Moreover, varying efficacy has been reported against the oncogenic gamma-herpesvirus subfamily [13] [14] [15] [16] [17] . Consequently, there is an urgent need for the continued development of anti-herpesvirus drugs, particularly targeting oncogenic herpesviruses.
RNA helicases contribute to the remodelling of intramolecular RNA, RNA-protein and protein-protein interactions in an ATPdependent manner 18 . Both viral and cellular RNA helicases have central roles in virus life cycles and have emerged as therapeutic targets 19 . Numerous studies have evaluated the potential of targeting virally encoded RNA helicases [20] [21] [22] . However, to circumvent viral resistance, inhibiting cellular RNA helicases has also been explored, supported by efforts targeting eIF4A for the treatment of cancer and DDX3 to inhibit HIV replication, illustrating that selective pharmacological targeting of RNA helicases is possible [23] [24] [25] . The KSHV open reading frame (ORF) 57 protein, which has a functional homologue in each human herpesvirus, is essential for viral lytic replication 26 . It is a multifunctional protein involved in all stages of viral mRNA processing via an interaction with the human transcription/export (hTREX) complex 27 . hTREX is a large multiprotein complex involved in Nxf1-mediated cellular bulk mRNA nuclear export. Notably, ORF57-mediated hTREX recruitment produces a viral ribonucleoprotein particle (vRNP) essential for KSHV lytic replication 28, 29 . ORF57 forms a direct interaction with the cellular export adapter Aly; however, redundancy in the cellular mRNA export pathway also allows ORF57 to facilitate vRNP formation via an interaction with UAP56-interacting factor 29, 30 . As such, disrupting the ORF57-hTREX interaction requires blocking multiple protein-protein interactions. Alternatively, the cellular RNA-helicase UAP56 functions as an essential hTREX assembly factor, forming an ATP-dependent trimeric complex with Aly and CIP29, as well as recruiting further hTREX components onto mRNAs (refs 31,32) . We therefore examined the potential of inhibiting UAP56 ATPase activity to prevent KSHV vRNP formation and lytic replication. In silico high-throughput screening identified small molecules capable of binding the UAP56 ATP-binding pocket. Strikingly, the results demonstrate that inhibiting UAP56 ATPase activity represents an antiviral target.
Results
KSHV vRNP formation is ATP-cycle-dependent. KSHV ORF57 interacts with hTREX to form an export-competent vRNP (ref. 33) . As the hTREX core component, UAP56, has RNAstimulated ATPase activity, we assessed whether ATP binding/ hydrolysis are required for ORF57-mediated vRNP formation. Coimmunoprecipitation assays were performed using lysates from HEK-293T cells transfected with green fluorescent protein (GFP) or GFP-UAP56 in the absence/presence of mCherry-ORF57, supplemented with 1.25 mM adenosine triphosphate (ATP) or a non-hydrolysable ATP analogue, adenosine 5′-O-(3-thio) triphosphate (ATPγS). The results showed that the ORF57-UAP56 interaction, hence vRNP formation, is ATP-dependent (Fig. 1a) .
ATP enhanced the interaction between ORF57 and endogenous hTREX proteins. Conversely, ATPγS significantly inhibited the ORF57-UAP56 interaction, highlighting the necessity of ATP hydrolysis for vRNP formation. Notably, Aly and CIP29 binding with UAP56 was unaffected by ATPγS, and a small, but significant, increase in binding could be observed compared to controls (Fig. 1b) . The effect of ATP and ATPγS on the ORF57-UAP56 interaction was dose-dependent ( Supplementary Fig. 1a ). Importantly, these results suggest that inhibiting ATP hydrolysis prevents ORF57-mediated vRNP formation, without disrupting endogenous hTREX.
Because ORF57-hTREX binding is disrupted by ATPγS, we speculated that UAP56 ATPase function is required for hTREX remodelling, enabling ORF57 association. Either the energy-generating step of ATP hydrolysis or its product, adenosine diphosphate (ADP), binding to UAP56 was responsible for the conformational change allowing ORF57 binding. Co-immunoprecipitation assays performed in the presence of ADP disrupted the UAP56-ORF57 interaction in a dose-dependent manner, indicating that ATP hydrolysis is the essential factor for the ORF57-hTREX interaction ( Fig. 1c,d ; Supplementary Fig. 1b) . However, ADP also disrupted endogenous hTREX. These data indicate an ATP-cycle-dependent remodelling of hTREX enabling vRNP formation (Fig. 1e) . Following ATP binding, endogenous hTREX is formed, and ATP hydrolysis then initiates a conformational change within hTREX, allowing ORF57 binding. After release of inorganic phosphate, bound ADP causes complex dissociation.
Screening for UAP56 ATPase inhibitors. We speculated that inhibitors targeting UAP56 ATPase activity would prevent ORF57-mediated vRNP formation. Importantly, ATPγS-based experiments indicate a potential to prevent vRNP formation while maintaining endogenous hTREX. In silico high-throughput screening (HTS) was used to identify small molecules capable of binding the UAP56 adenine-binding site, based on the UAP56: CI P2 9 Al y Figure 1 | ATP-cycle-dependent remodelling of hTREX affects ORF57-mediated vRNP formation. a, Immunoprecipitations of GFP or GFP-UAP56, co-expressed in the absence or presence of mCherry-ORF57. Precipitations were performed with HEK-293T whole cell lysates (Input) in the absence of any additional nucleotides or in presence of 1.25 mM ATP or 1.25 mM ATPγS. Samples were analysed by western blotting using the indicated antibodies. b, Quantification of four independent immunoprecipitations (performed with mCherry-ORF57, as shown in a, or Myc-ORF57). Values are averages and error bars represent standard deviation (s.d.), n = 4. **P < 0.01, *P < 0.05, effect of ATP or ATPγS compared to untreated, using an unpaired t-test. c, Immunoprecipitations of GFP-UAP56 after co-expression with mCherry-ORF57. Precipitations were performed with HEK-293T whole cell lysate (Input) in the absence of any additional nucleotides or with increasing concentrations of nucleotides, as indicated. Samples were analysed by western blotting using the indicated antibodies. d, Quantification of three independent immunoprecipitations (at concentrations of 1.25 or 1.75 mM ATP, ATPγS or ADP). Values are averages and error bars represent s.d., n = 3. *P < 0.05, **P < 0.01 or ***P < 0.001, effect of ATP or ATPγS compared to untreated, using an unpaired t-test. e, Schematic representation of ATP-cycle-dependent remodelling of central hTREX components and the ORF57-mediated vRNP. The proposed model is based on the immunoprecipitations shown in a-d.
ADP co-crystal structure 34 . Favoured compounds were tested for their potential to inhibit recombinant UAP56 ATPase activity. The most potent compound, CCT018159 (Fig. 2a) , reduced UAP56 activity by >70% at 100 µM. Molecular modelling predicted that CCT018159 binds the UAP56 ADP-binding pocket, with the resorcinol substructure mimicking the adenine unit of ADP and the methyl group at the 5-position of the pyrazole ring projecting towards the phosphate channel ( Fig. 2b-d) . The molecule forms hydrogen-bonding interactions from the resorcinol hydroxyls to His67, Glu66 and Gln72, and a π-stacking interaction from the aryl ring to Phe65. The rest of the interactions are hydrophobic in nature (Met93, Gly92, Gly94 and Gly64). UAP56 inhibition was dose-dependent, with nonlinear regression determining a half maximal inhibitory concentration (IC 50 ) of 64.3 ± 2.5 µM (mean ± s.e.m.) (Fig. 2e) .
CCT018159 has previously been identified as a heat shock protein 90 (HSP90) inhibitor 35 , so we calculated the inhibitory constant (K i ) to compare the affinities towards UAP56 and HSP90; this value takes the enzyme and substrate concentrations used in biochemical assays into account. Using the published Michaelis constant (K M ) value for UAP56 ATP binding 36 , we calculated a K i value of 5.5 ± 0.2 µM for CCT018159, similar to the reported K i of 1.8 ± 0.3 µM of CCT018159 against HSP90 (ref. 37) . To examine the specificity of CCT018159 against UAP56, we used 17-DMAG, an alternative HSP90 inhibitor, but found no UAP56 ATPase inhibition ( Supplementary Fig. 2a ). Microscale thermophoresis also confirmed CCT018159-UAP56 binding ( Fig. 2f and Supplementary Fig. 2b,c) , yielding a dissociation constant, K D of 76.0 ± 3.8 μM, indicating relatively weak binding in a similar range to its natural substrate, ATP (K D = 30.1 ± 4.5 µM). Finally, using an ADP-displacement assay, we confirmed that CTT018159 is an ATP/ADP-competitive inhibitor binding in the UAP56 adenine-binding pocket (Fig. 2g) . Notably, these assays used recombinant UAP56 in the absence of any cellular cofactors, apart from RNA, which may affect the CCT018159-UAP56 binding affinity, as hTREX components stimulate UAP56 ATPase activity 32 .
CCT018159 disrupts vRNP formation without inhibiting cellular mRNA export. The effect of CCT018159 on vRNP formation was assessed using co-immunoprecipitation assays. 3-(4,5-Dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays identified non-cytotoxic concentrations in HEK-293T cells (<15 µM; Fig. 3a ). Cells were transfected with GFP or ORF57-GFP, then incubated in the absence/presence of a concentration series of CCT018159. After 24 h, co-immunoprecipitations were performed using an UAP56-specific antibody, again in the absence/presence of CCT018159. CCT018159 effectively reduced the ORF57-UAP56 interaction at 2.5 and 5 µM concentrations, while maintaining endogenous hTREX formation (Fig. 3b) . Furthermore, up to 0.5 mM CCT018159 added to the lysate did not inhibit the hTREX-UAP56 interaction ( Supplementary Fig. 3a ). To confirm UAP56-specific inhibition, co-immunoprecipitations were repeated in the absence/ presence of a concentration range of 17-DMAG showing minimal cytotoxicity ( Supplementary Fig. 3b,c) . Encouragingly, the ORF57-UAP56 interaction was not disrupted, indicating that CCT018159-mediated vRNP disruption is due to UAP56 inhibition. Additionally, ORF57-mediated nucleolar redistribution of hTREX components was also assessed 38 . CIP29 localizes to the nuclear speckles excluding the nucleolus; however, upon ORF57 expression, CIP29 is redistributed and co-localizes with nucleolar ORF57 (ref. 39 ). Conversely in CCT018159-treated cells, ORF57 failed to redistribute CIP29 to the nucleolus, with both proteins localizing independently in the nuclear speckles ( Supplementary Fig. 3d ).
Following effective vRNP disruption in vitro and in cell culture, we examined the effect of CCT018159 on ORF57-mediated mRNA processing. Cells were transfected with GFP or ORF57-GFP and a viral intronless ORF47 mRNA reporter construct, then treated with DMSO or CCT018159 for 18 h, and ORF47 mRNA levels were assessed in whole cell and cytoplasmic lysates (Fig. 3c) . The ORF57-hTREX interaction stabilizes viral mRNAs, allowing efficient viral mRNA export 40 and the results confirmed an increase in whole cell and cytoplasmic ORF47 mRNA abundance. In contrast, CCT018159 reduced both ORF47 mRNA stabilization and export, with no significant difference over GFP-transfected controls. Together, the data suggest that CCT018159 prevents vRNP formation and downstream mRNA processing.
ORF57-hTREX binding results in a block of cellular bulk mRNA nuclear export 11 . Therefore, if CCT018159 disrupts ORF57-mediated vRNP formation without affecting endogenous hTREX, cellular bulk mRNA export should be restored. Fluorescence in situ hybridization (FISH) was used to monitor cellular bulk mRNA export (Fig. 3d) . In GFP-expressing cells, the majority of polyadenylated RNA (poly(A)-RNA) was detected in the cytoplasm, with minor amounts in nuclear speckles. However, ORF57-mediated hTREX sequestration led to a marked reduction of cytoplasmic poly (A)-RNA and retention in the nucleus. Strikingly, in ORF57-expressing cells treated with CCT018159, nuclear retention was lost, with poly(A)-RNA present in the cytoplasm. Quantification of the FISH analysis showed this effect to be significant (Fig. 3e) . Importantly, the results demonstrated that CCT018159 does not affect endogenous hTREX. The results were confirmed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis, measuring the export of selected cellular mRNAs in the absence/presence of CCT018159 ( Supplementary Fig. 3e ). FISH analysis was repeated in the presence of 17-DMAG, which failed to relieve ORF57-mediated nuclear retention of cellular bulk mRNA ( Supplementary Fig. 3f,g ). This confirms CCT018159-mediated UAP56 inhibition, independent of HSP90. Samples were analysed by western blotting using the indicated antibodies. Results are representative of three independent repeats at varying concentrations. c, HEK-293T cells co-expressing GFP or ORF57-GFP and the intronless reporter construct ORF47 were treated with DMSO or 2.5 µM CCT018159. qRT-PCR was performed after subcellular fractionation. ORF47 transcript levels were normalized to GAPDH and the relative increase calculated using the ΔΔCT method. Values are averages, n = 3, error bars display s.d., *P < 0.05 or ***P < 0.001, effect CCT018159 compared to DMSO-treated, using an unpaired t-test. CCT018159 prevents KSHV lytic replication. ORF57-mediated vRNP formation is essential for KSHV lytic replication 33 . We therefore examined the potential of CCT018159 to inhibit KSHV replication using the KSHV-infected cell line TREx BCBL1-Rta (ref. 41) . MTS assays and nonlinear regression determined the cytotoxic concentration 50 (CC 50 ) for 24 and 72 h time points (Fig. 4a,b) . Furthermore, no increase in apoptosis was observed at 2.5 μM CCT018159 ( Supplementary Fig. 4a ), contrary to the observed effect of HSP90 inhibitors in KSHV-infected cell lines 42, 43 . TREx BCBL1-Rta cells remained latent or were reactivated with doxycycline and treated with increasing amounts of CCT018159. Immunoblotting using Myc and ORF57-specific antibodies (markers for induction of lytic replication) or the KSHV minor capsid protein (mCP)-specific antibody (viral lytic late protein dependent on vRNP assembly) showed a marked reduction in mCP expression at 2.5 μM CCT018159 ( Fig. 4c; Supplementary Fig. 4b ), whereas no decrease in ORF57 expression is noted, confirming the decrease in mCP expression is not due to loss of ORF57 or lower reactivation levels ( Supplementary Fig. 4b,c) . Moreover, ORF57 is translated from an intron-containing transcript, indicating functional hTREX. Quantification and nonlinear regression of mCP levels gave an effective concentration 50 (EC 50 ) for viral protein expression. Importantly, the EC 50 of 0.6 μM is far lower than the CC 50 of 21 μM at this time point. A large 'therapeutic window' is observed, showing that cytotoxicity occurred at higher concentrations than inhibition of viral protein expression (Fig. 4c) .
To assess whether CCT018159 also decreased viral genome replication and virion production, uninduced or reactivated TREx BCBL1-Rta cells were treated with increasing amounts of CCT018159, and quantitative polymerase chain reaction (qPCR) was used to determine viral load. A steep decrease in viral load was visible at 1 and 2.5 μM CCT018159 (Fig. 4d) . Nonlinear regression calculated an EC 50 on viral replication of 1.1 μM. Again, when compared to the 72 h CC 50 of 16.6 μM, a large 'therapeutic window' was observed. This concentration range produced dramatic inhibition of viral replication without any cytotoxicity. To examine virion production, supernatants were used to re-infect naive cells, and qRT-PCR was used to determine KSHV gene expression. Cells re-infected with supernatant from CCT018159-treated cells contained 80% less viral mRNA than controls (Fig. 4e) . Together, the results suggest that CCT018159 is effective at inhibiting KSHV lytic replication and virion production.
To confirm that CCT018159-mediated inhibition of KSHV replication is due to vRNP disruption and not HSP90 inhibition, we performed MTS and viral load assays using 17-DMAG. Although a therapeutic window was observed-CC 50 of 4.3 ± 0.9 μM and EC 50 of 0.04 ± 0.01 μM (Supplementary Fig. 4d )-we noticed irregularities for both assays. The metabolic activity, reflecting cell viability, was initially increased, before decreasing at higher concentrations. This 17-DMAG-induced cellular stress resulted in increased levels of apoptosis and necrosis ( Supplementary  Fig. 4e ). This was in contrast to CCT018159, but reflects published results showing HSP90 inhibitors cause apoptosis 43, 44 via vFLIP degradation and subsequent downregulation of the NF-κB signalling pathway 43, 44 . Importantly, NF-κB signalling is significantly reduced in 17-DMAG-treated cells compared to CCT018159 (Supplementary Fig. 4f ). Moreover, a decrease in viral load following 17-DMAG treatment not only indicated a block in lytic reactivation, but also viral episome loss via KSHV latent nuclear antigen (LANA) degradation 42 . Immunoblotting showed enhanced LANA and CDC2 degradation in the presence of 17-DMAG ( Supplementary Fig. 4g ), whereas no LANA degradation was observed for a range of concentrations of CCT018159, although CDC2 levels were reduced from 5 µM. Notably, KSHV mCP inhibition occurred at concentrations of 1-2.5 µM CCT018159 ( Supplementary Fig. 5a -c). These data confirm that CCT018159-mediated inhibition is due to vRNP disruption, not HSP90-related inhibitory mechanisms.
Effect of CCT018159 structural analogues on KSHV replication.
To assess a structure-activity relationship, four structural analogues of CCT018159 were analysed (Table 1 ; Supplementary Figs 6-9 ). An IC 50 was determined for all analogues against recombinant UAP56 in vitro. The CC 50 on TREx BCBL1-Rta cells was assessed by MTS assay and the inhibitory potential (EC 50 ) on viral protein production and genome load also determined. Furthermore, immunoprecipitations were used to test those compounds effective against KSHV lytic replication for their ability to disrupt the UAP56-ORF57 interaction (Supplementary Figs 6f, 7f and 8f ). All analogues present minor structural variations on CCT018159 at the 2,4-hydroxyphenyl, benzodioxanyl and pyrazole subsites. Removal of the ethyl group at the resorcinol substructure (compound 2) was not detrimental to activity and showed similar inhibitory effects on KSHV replication, consistent with molecular modelling in which the ethyl group extends into solvent (Fig. 2d) . Replacement of the methyl group at the 5-position of the pyrazole ring with a carboxylic acid (compound 4) ablated any inhibitory activity, suggesting that the carboxylate group is not tolerated at the entrance to the phosphate channel, possibly due to its charged nature and relative proximity to two carbonyl groups (Gly92, Thr96) inducing a repulsive interaction. Supportive of this hypothesis, re-docking of the compound failed to generate a binding pose. Replacement of the dioxanyl ring with a methoxy group (compound 3) and H (compound 1) demonstrated a modest reduction of ATPase activity and KSHV inhibition, consistent with molecular modelling demonstrating a reduced potential for hydrophobic contact to the side chain of Met93. The analogues were also tested for HSP90 inhibition. Notably, combining the results with virus inhibition, a larger therapeutic window was observed for compound 1 ( Supplementary Fig. 10a-c) . CDC2 expression was unaltered below 15 μM, whereas effective mCP inhibition occurred between 2.5 and 5 μM. Compound 2 showed a marked decrease in expression for both mCP and CDC2 at 2.5 μM, suggesting an efficient HSP90 inhibitor ( Supplementary Fig. 11a-c) . Distinct responses were thus observed for all compounds, with CCT018159 and compound 1 showing specific inhibition of virus replication by inhibiting UAP56.
CCT018159 inhibits α-and β-herpesvirus replication. All herpesviruses encode an ORF57 homologue that uses hTREX components for vRNP assembly. To examine any potential pan-herpesvirus activity, we assessed the inhibitory effect of CCT018159 on the α-and β-herpesviruses HSV-1 and HCMV, respectively. First, immunoprecipitations of UAP56 were repeated in the presence of the ORF57 homologues, HSV-1 ICP27 and HCMV UL69 (Fig. 5a,b) . Notably, CCT018159 reduced the interaction of both viral proteins and hTREX to a level similar to that observed for ORF57. Furthermore, a non-cytotoxic working concentration of CCT018159 in human foreskin fibroblast (HFF) cells was determined (Fig. 5c,d ), cells were then infected with HSV-1, before treatment with increasing amounts of CCT018159. Cells were directly imaged for HSV-mediated cell lysis ( Supplementary  Fig. 12a ) or assessed using a plaque assay (Fig. 5e ). Strikingly, with increasing concentrations of CCT018159, cell lysis, plaque size and plaque number were dramatically decreased, demonstrating efficient inhibition of HSV-1 replication. Moreover, a marked reduction in virion production was observed after re-infection with the harvested supernatant and assessment by flow cytometry ( Fig. 5f and Supplementary Fig. 12b ), plaque assay ( Fig. 5g) and immunoblotting of the lytic protein, ICP27 ( Supplementary Fig. 12c ). CCT018159 (2.5 μM) resulted in a 50% reduction in infected cells, with a 95% reduction observed at 5 μM CCT018159. Inhibition of HCMV lytic replication was assessed after infection of HFF cells and treatment with CCT018159. Cells were directly imaged for HCMV-mediated cell lysis ( Supplementary Fig. 12d) , and re-infection levels were quantified by qPCR (Fig. 5h) . Excitingly, 1 µM CCT018159 was found to reduce HCMV virion production by 50%, with over 99% reduction at 2.5 µM. Importantly, a 90% reduction of infectious HSV-1 or HCMV virion production was determined at 2.5 or 5 μM CCT018159, where no inhibition of HSP90 occurred ( Supplementary Fig. 13a-c) , providing a clear therapeutic window. Together, these results show that CCT018159 has pan-herpesvirus activity.
Discussion
Disrupting the ORF57-hTREX interaction is an antiviral target; however, strategies to block this interaction are complicated by redundancy in the mammalian mRNA export system 29 . We therefore targeted the ATP-cycle-dependent remodelling of hTREX required for vRNP formation. The UAP56 ATP-binding site is situated in a cleft between two connected helicase domains 34, 45 , with ATP binding believed to bring these domains closer, enabling Molecular modelling predicts that CCT018159 binds the UAP56 adenine-binding pocket, suggesting an ATP-competitive inhibitor. Although CCT018159 was found to inhibit purified UAP56 and displace ADP with an IC 50 of ∼60 µM, its antiviral effect was detected at 30-fold higher potency (around 2 µM). As it has previously been shown that hTREX proteins Aly and CIP29 stimulate UAP56 ATP binding and hydrolysis 31 , it is not surprising that the affinity of UAP56 for CCT018159 should also change in the presence of cellular cofactors. CCT018159 is a known HSP90 inhibitor 35 , demonstrating complex pharmacokinetics, including relatively high metabolic turnover, but its favourable selectivity profile against closely related ATPases and a panel of kinases 37, 47 make it a useful starting point for lead compound development. The data conclusively show CCT018159-mediated UAP56 inhibition, disruption of the ORF57-hTREX interaction and lytic replication, with a differing phenotype from the HSP90-inhibitor, 17-DMAG. Nonetheless, as CCT018159-mediated HSP90 inhibition occurred at higher concentrations, restricting the therapeutic window, CCT018159 should be seen as a proof of principle and a starting point for the development of UAP56-specific antivirals. We have identified analogues that demonstrate altered HSP90 inhibition, an important selection criterion for lead-generation UAP56 inhibitors. Future work will explore potential enhanced potency via extension into the phosphate channel. Targeting a cellular RNA helicase can be assumed to reduce the risk for virus resistance and theoretically provides pan-viral activity. Notably, all herpesviruses encode ORF57 homologues, and hTREX interactions are essential for their replication 33, 48, 49 . Excitingly, CCT018159 prevents replication of all three herpesvirus subfamilies, indicating possible pan-herpesviral activity and may have wider use, as other important human pathogens co-opt UAP56 for viral mRNA processing 50 .
Methods
Virtual high-throughput screening. Identification of UAP56 ATPase inhibitors was performed using virtual high-throughput screening of a University of Leeds proprietary 250k library of small molecules selected from the ZINC 12 database 51 , based on high structural diversity, adherence to Lipinski criteria and absence of pan interference (PAIN) scaffolds. Docking routines were performed using eHiTS (SymBioSys) and AutoDock4 (Scripps Research Institute) based on the UAP56Δ9 MgADP complex (1XTJ). Prior to docking ADP, Mg and the water molecules were removed and the protein was prepared using the default settings within the Protein Preparation Wizard within Maestro9.4 (Schrödinger). eHiTS was used to screen the 250k library using a clip file generated around the ATP binding site and highest speed docking (accuracy mode 1). The 5k compounds that demonstrated the best eHiTS score based on the default scoring function with the software were re-docked using AutoDock4. Favoured compounds (400) were selected for screening based on the default AutoDock4 scoring function and visualized for quality of binding mode and for compliance with attractive physicochemical properties (Lipinski's rules) and availability.
ATPase assay and compound screening. For the UAP56 ATPase assay 2.5 μM purified GST-UAP56 and, where applicable, GST were incubated with 50 μM yeast tRNA, 35 μM ATP, 2 mM MgCl 2 and 50 mM KCl in 50 mM Tris/HCl (pH 7.6). During compound screening, inhibitors were added to give final concentrations of 100 μM. For IC 50 measurements, compounds of varying concentrations were delivered in 0.5 μl DMSO (1% of total reaction volume). Reactions were incubated at 37°C for 30 min, before Kinase-Glo Reagent (Promega) was added according to the manufacturer's instructions to quantify the remaining ATP by luminescence. All replicates were of a biological nature.
ADP displacement assay. To assess competitive binding of CCT018159 to UAP56, an ATPase assay (as described above) containing 5 μM UAP56-GST and 5 μM ATP was run for 30 min, to ensure all UAP56 was bound to ADP. Using an ADP-Glo Kinase assay kit (Promega) following the manufacturer's instructions, any remaining ATP was depleted, before CCT018159 was added in increasing concentrations and the reaction mixture was incubated at 37°C for 30 min. Using the kit's reagents, all free ADP was converted to ATP and quantified by luminescence. All replicates were of a biological nature.
Viral mRNA export assay. HEK-293T cells were co-transfected with GFP or ORF57-GFP and ORF47 expression constructs before subcellular fractionation. Quantitative qRT-PCR was performed on isolated RNA. Levels of the reporter mRNA ORF47 were normalized to GAPDH and used to quantify viral mRNA export. The method has been described previously 29, 38 . All replicates were of a biological nature.
Fluorescence in situ hybridization. HEK-293T cells were transfected with GFP or ORF57-GFP for 6 h and subsequently treated with DMSO, CCT018159 or 17-DMAG for 24 h. Polyadenylated RNA was detected in with an oligo dT(70) probe labelled at the 5′ end with Alexa Fluor 546 NHS Ester. The method was performed as published previously 31 . Cells were visualized on a Zeiss LSM 700 laser scanning confocal microscope and images were analysed using Zen 2011 (Zeiss).
Infectious KSHV virion production. TREx BCBL1-Rta cells were collected 72 h after reactivation of viral lytic replication. Filtered tissue culture supernatants were used 1:1 to inoculate 1 × 10 6 HEK-293T cells. Infected cells were quantified at 24 h post-infection by real-time qRT-PCR. RNA was extracted from total cell lysates using TRIzol (Invitrogen) as described by the manufacturer. RNA was DNasetreated using the Ambion DNase-free DNA removal kit, as per the manufacturer's instructions, and RNA (1 μg) from each fraction was reverse transcribed with M-MuLV reverse transcriptase (New England Biolabs), according to the manufacturer's instructions, using oligo(dT) primers (Sigma-Aldrich). Obtained cDNA served as the template for qPCR reactions using ORF47, ORF57 and GAPDH specific primers as described before. Replicates were of a biological nature, with each used for two technical repeats.
Plasmids and antibodies. pGST-UAP56, pEGFP-UAP56, pORF47, pORF57-EGFP, pICP27-EGFP, pUL69-EGFP and pmCherry-ORF57 have been described previously 11, 30, 31, 33, 49, 52 . pEGFP-N1 expressing eGFP (Clontech) and pGEX-4T.1 expressing GST (GE Healthcare) are commercially available. Antibodies against Aly (11G5) (Sigma-Aldrich), GAPDH (6C5) (Abcam), GFP (JL-8) (Clontech), ORF57 (207.6) (Santa Cruz Biotech), UAP56 (rabbit polyclonal) (Abcam), CHTOP (rabbit polyclonal) (Bethyl Laboratories), mCP (sheep polyclonal) (Exalpha Biological,), CDC2 (A17) (Abcam), HSP90 (4F10) (Santa Cruz Biotech), LANA (13B10) (Leica Biosystems) and ICP27 (vP-20) (Santa Cruz Biotech) were obtained from the respective companies. CIP29 antibody was a gift from Stuart Wilson (University of Sheffield) 31 . In general, antibodies were used for western blot analysis at a concentration of 1:5,000, ORF57, ICP27, HSP90 and mCP were used at a 1:1,000 dilution, CIP29 was used at a 1:2,500 dilution.
Cell culture and viruses. HEK-293T cells were purchased from ATCC (American Type Culture Collection) and HFF cells were a gift from J. Sinclair (University of Cambridge). Both cell lines were cultured in Dulbecco's modified Eagle's medium with glutamine (DMEM, Lonza) supplemented with 10% fetal calf serum (FCS, Gibco) and 1% penicillin-streptomycin (Gibco). TREx BCBL1-Rta cells, a human B-cell lymphoma cell line latently infected with KSHV and modified to contain doxycycline (dox)-inducible myc-RTA, were a gift of J. U. Jung (University of Southern California) 41 . TREx BCBL1-Rta cells were grown in RPMI1640 growth medium with glutamine (Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) and 1% penicillin-streptomycin (Gibco). For virus reactivation, 0.8 × 10 6 cells TREx BCBL1-Rta cells were induced using 2 µg ml -1 doxycycline hyclate (Sigma-Aldrich). Cells were collected after 24 h for analysis of protein expression, while viral load and production of new infectious virions was assessed after 72 h. HCMV (Merlin) and HSV-1 virus (SC16) stocks were provided by J. Sinclair and S. Efstathiou (University of Cambridge). For each cell line a large bank of cell stocks were established that were used throughout the duration of the project. To reduce any impact of phenotypic drift, prokaryotic contamination and inadvertent crosscontamination, cell cultures were discarded after 15 passages and new cultures established from the bank. Used cell lines were tested negative for Mycoplasma in November 2014 and January 2016.
Co-immunoprecipitation assays. A total of 1 × 10 6 HEK-293T cells were co-transfected with 1 µg of the indicated plasmid DNA (GFP, GFP-UAP56, mCherry-ORF57, ORF57-GFP, ICP27-GFP or pUL69-GFP) using Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). Where indicated, cells were treated with CCT018159 6 h after transfection. After 24 h, transfected cells were lysed on ice for 20 min using 1 ml modified RIPA buffer (50 mM Tris/HCl, 150 mM NaCl, 1% NP40-alternative, pH 7.6) with the addition of 1 μl ml -1 RNase A (Invitrogen). Lysates were clarified for 10 min at 16,000g and the supernatants were pre-cleared against protein A beads (Roche) for 2 h at 4°C with end-over-end mixing. For the precipitations, 1 ml of pre-cleared lysate was incubated with 15 μl pre-washed GFP-trap affinity beads (ChromoTek) and the indicated amounts of ATP, ADP (Sigma-Aldrich) or ATPγS (Jena Bioscience) for 2.5 h at 4°C while end-over-end mixing. Alternatively, cell lysates were incubated with 5 μg polyclonal UAP56 antibody for 16 h at 4°C while end-over-end mixing, before addition of Protein A agarose beads (Roche) for another 2 h. Where indicated, small-molecule inhibitors were added in DMSO or EtOH, yielding a total of 0.1% DMSO or 0.5% EtOH per immunoprecipitation, which was also supplemented in all control precipitations. Beads were washed four times in ice-cold modified RIPA buffer and proteins were eluted in Laemmli buffer before analysis by western blotting as previously described 53 .
Immunoblotting. Western blots were performed as previously described 33 . Briefly, protein samples were run on 10-12% polyacrylamide gels and transferred to nitrocellulose Hybond-C (GE Healthcare) membranes via tank blotting. Membranes were blocked with TBS + 0.1% vol/vol Tween 20 and 5% wt/vol dried skimmed milk powder. Membranes were probed with relevant primary and secondary horseradish peroxidase conjugated IgG antibodies (Dako), treated with EZ-ECL (Geneflow), and exposed to Hyperfilm ECL (GE Healthcare).
Recombinant protein expression. Recombinant GST and GST-UAP56 were expressed in E. coli BL-21 at 30°C overnight and purified as described previously 13, 28, 54 . Proteins were eluted from the beads using 50 mM Tris/HCl (pH 7.6) with 10 mM reduced glutathione and then further purified by buffer exchange using PD midiTrap G-25 columns (GE Healthcare) and 50 mM Tris/HCl, 50 mM KCl, 2 mM MgCl 2 , pH 7.6).
Microscale thermophoresis. Microscale thermophoresis (MST) was carried out on a Monolith NT.115 Microscale Thermophoresis device using standard treated capillaries (NanoTemper Technologies). Recombinant GST-UAP56 was labelled with FITC (Sigma-Aldrich) according to the manufacturer's instructions. Labelling reagent was removed by buffer-exchange chromatography using Zeba Spin Desalting Columns following the manufacturer's instructions and eluted into 20 mM HEPES (pH 7.4) with 2 mM MgCl 2 . The concentration of labelled protein used was set between 100 and 500 nM by diluting labelled protein in 20 mM HEPES (pH 7.4) with 2 mM MgCl 2 . Light-emitting diode power was set to 10-60%. All reactions were performed at 37°C. Equal amounts of labelled protein were titrated by CCT018159 diluted in DMSO and 20 mM HEPES (pH 7.4) with 2 mM MgCl 2 in a 1:1 series dilution starting with 4.5 mM CCT018159, such that the final concentration of DMSO was 20% (vol/vol) in all capillaries. Curve fitting and K D determination was performed using the NTanalysis software (NanoTemper Technologies) in the Thermophoresis mode. All replicates were of a biological nature.
Cell viability assay. Cell viability was measured in HEK-293T, TREx BCBL1-Rta and HFF cells using an MTS-based CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (Promega), following the manufacturer's instructions. HEK-293T cells were seeded at a concentration of 0.5 × 10 6 cells per ml and HFF cells at 1 × 10 5 cells per ml, 24 h before treatment with small-molecule inhibitors. TREx BCBL1-Rta cells were seeded at 1 × 10 6 cells per ml and treated immediately. The indicated inhibitor concentrations were delivered in DMSO (0.1% of total volume), which was also added to all control wells, and incubated for 24 or 72 h, before cell viability was assessed. All replicates were of a biological nature.
Apoptosis assay. Apoptotic and necrotic cells were stained using the Annexin-V-FLUOS Staining Kit and protocol from Roche. In brief, TREx BCBL1-Rta cells were treated with DMSO, CCT018159 or 17-DMAG for 72 h, before they were washed and incubated in a HEPES buffer containing Annexin-V-Fluorescein and propidium iodide to label apoptotic and necrotic cells. Cells were analysed using a flow cytometer. All replicates were of a biological nature.
Immunofluorescence. Cell fixation and staining were performed as previously described 55 . Briefly, HEK-293T cells were grown on sterilized glass coverslips treated with poly-L-lysine before being transfected. After 24 h, cells were washed in PBS and fixed in PBS containing 4% (vol/vol) paraformaldehyde for 10 min, washed twice in PBS and permeabilized using PBS containing 1% Triton X-100 for 10 min. Coverslips were then incubated with appropriate primary and secondary antibodies for 1 h each at 37°C before being mounted onto microscope slides using Vectashield with 4′,6-diamidino-2-phenylindole (DAPI). Slides were visualized on a Zeiss LSM 700 laser scanning confocal microscope and images were analysed using Zen 2011 (Zeiss).
KSHV replication assay. To determine the viral-DNA load, TREx BCBL1-Rta cells were collected 72 h after reactivation of viral lytic replication. Total DNA was isolated using the QIAamp DNA mini kit (Qiagen) following the manufacturer's instructions and quantified by ultraviolet spectrophotometry. Quantification of viral DNA copy numbers was performed using a Rotor-Gene 6000 Real-Time PCR machine (Qiagen). Amplification was performed in 20 µl reaction volumes with 40 ng template DNA using SensiMix Plus SYBR qPCR reactions (Bioline) according to the manufacturer's instructions, with a standard three-step melt program (95°C for 15 s, 60°C for 30 s, 72°C for 20 s). Amplifications of the viral gene ORF57 were carried out using the forward primer 5′-TGTCAGTGGTGGACCTGAC and reverse primer 5′-GTGGTCGTTGAGGGCAATG. The viral gene ORF47 was amplified using the forward primer 5′-CGCGGTCGTTCGAAGATTGGG and reverse primer 5′-CGAGTCTGACTTCCGCTAACA. GAPDH was amplified using the forward primer 5′-GCCATAATCAAGCGTACTGG and reverse primer 5′-GCAGACAAATATTGCGGTGT. Quantitative analysis for viral DNA levels with GAPDH as internal control was carried out using the comparative CT method as described previously 38 . Replicates were of a biological nature, with each used for two technical repeats.
Primary HSV-1 infection. A multiplicity of infection (MOI) of 0.001 was used for primary infection of 2 × 10 5 HFF cells with HSV-1. Following 1 h incubation of the cells with virus, cells were washed twice with PBS, followed by addition of growth medium (for analysis of infectious HSV-1 virion production) or plaque agar (for HSV-1 plaque assays of primary infection). Both growth medium and plaque agar were supplemented with small-molecule inhibitor concentrations or DMSO (at a final concentration of 0.1% DMSO in all wells).
Infectious HSV-1 virion production. After 72 h primary HSV-1 infection, cell supernatants were diluted 1:10-10,000 with new growth medium and incubated on 2 × 10 5 naive HFF cells. Re-infection was analysed by plaque assay (below) or using flow cytometry. For the latter, cells were incubated with infectious virions from a primary infection for 24 h, fixed using PBS with 4% (vol/vol) paraformaldehyde, and washed twice again with PBS. As a recombinant virus expressing GFP was used, all HSV-1-infected cells were quantified via fluorescence using the BD LSRFortessa flow cytometer (BD Biosciences) on the FITC channel. All replicates were of a biological nature.
HSV-1 plaque assay. Plaque assays were performed after primary infection or re-infection of naive HFF cells with HSV-1, as described above. After 1 h incubation of 2 × 10 5 HFF cells with HSV-1, cells were washed twice with PBS and overlaid with plaque agar (1:1 dilution of growth media with 2% (wt/vol) molten agarose, tempered to 37°C). Small-molecule inhibitors were added to plaque agar during primary HSV-1 infections, and re-infection for assessment of infectious HSV-1 virion production was performed without additional inhibitors. The agarose was removed after 96 h, cells were washed once with PBS, fixed for 10 min with 4% (vol/vol) paraformaldehyde and stained using 0.5% (wt/vol) crystal violet stain. Viral plaques were counted by eye. All replicates were of a biological nature.
Primary HCMV infection. MOIs of 0.08 and 0.008 were used for primary infection of 2 × 10 5 HFF cells with HCMV. Following 1 h incubation of cells with virus, the growth medium was supplemented with small-molecule inhibitor concentrations or DMSO (at a final concentration of 0.1% DMSO in all wells).
Infectious HCMV virion production. After 168 h primary HCMV infection, HFF cell supernatants were diluted 1:10 and 1:100 (for initial infection with an MOI of 0.08) or 1:10 (for initial infection with an MOI of 0.008) with new growth medium and incubated on 2 × 10 5 naive HFF cells for 20 h. Re-infection rates were measured by quantitative PCR. For this, total DNA was isolated using the QIAamp DNA mini kit (Qiagen) following the manufacturer's instructions and quantified by UV spectrophotometry. Quantification of viral DNA copy numbers was performed using a Rotor-Gene 6000 Real-Time PCR machine (Qiagen). Amplification was performed in 20 µl reaction volumes with 40 ng template DNA using SensiMix Plus SYBR qPCR reactions (Bioline), according to the manufacturer's instructions, with a standard three-step melt program (95°C for 15 s, 60°C for 30 s, 72°C for 20 s). Amplifications of the viral gene UL69 were carried out using the forward primer 5′-TCGGTGGGATGAATTTGGTC and reverse primer 5′-CATGATAGCGTACTGTCCCTTC. GAPDH was amplified using the forward primer 5′-GCCATAATCAAGCGTACTGG and reverse primer 5′-GCAGACAAATATTGCGGTGT. Quantitative analysis for viral DNA levels with GAPDH as internal control was carried out using the comparative CT method as previously described 38 . Replicates were of a biological nature, with samples from one concentration series used for a control technical repeat.
Synthesis and characterization of compounds. Compounds 3 and 4 were synthesized according to the methods described in the following. All reactions were carried out under a normal atmosphere and were stirred with a magnetic stirrer unless otherwise stated. All reagents were obtained from commercial sources and were used without further purification. Anhydrous solvents were dried by passing through aluminium oxide.
Analytical thin-layer chromatography (TLC) was performed on aluminium precoated silica gel plates (254 µm) supplied by Merck Chemicals and visualized by ultraviolet light (254 nm). Preparative flash column chromatography was carried out using Thomson Single Step pre-packed silica cartridges (4-25 g) on a Biotage Isolera Flash Purification system, or dry flash vacuum chromatography using 43-65 µm silica. High-resolution mass spectrometry was carried out using a VG Autospec mass spectrometer operating at 70 eV, using electron spray ionization (ES+), correct to four decimal places. Analytical high-performance liquid chromatography (HPLC) was performed on an Agilent 1290 Infinity Series equipped with an ultraviolet detector and Hyperprep C-18 column with a gradient of acetonitrile and water (5-95%) and 0.1% trifluoroacetic acid, at a flow rate of 0.5 cm 3 min −1 over a period of 5 min.
Proton ( 1 H) and carbon ( 13 C) NMR spectra were recorded on a 300/75MHz Bruker DPX300 or a 500/125 MHz Bruker Advance 500 Fourier transform spectrometer as indicated. Chemical shifts (δ) are reported in parts per million (ppm) and are reported with reference to the residual solvent peak. Samples were prepared in either deuterated chloroform (CDCl 3 ) or deuterated dimethylsulfoxide (DMSO-d 6 ), as indicated. Multiplicities are reported with coupling constants J in hertz and are uncorrected. Spectra were assigned with the aid of two-dimensional correlation spectroscopy (2D-COSY), performed on the same equipment as detailed above.
Infrared spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer. Vibrational frequencies are reported in wavenumbers (cm −1 ). Melting points were recorded on a Griffin melting point apparatus and are reported uncorrected.
Compound 3 was synthesized in three steps from commercially available reagents, as follows.
1-(5-Ethyl-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone. To a vessel containing 4-ethylresorcinol (2.20 g; 16.0 mmol; 1.0 equiv.) and 4-methoxyphenylacetic acid (2.64 g; 16.0 mmol; 1.0 equiv.) was added boron trifluoride diethyl etherate (10 ml 0.08 mol; 5.0 equiv.), and the resulting slurry was heated to 90°C for 2 h with stirring, then allowed to cool. The reaction mixture was then poured slowly over sodium acetate solution (10% wt/vol aq.; 100 ml) and stirred for 1 h. The resulting mixture was extracted with ethyl acetate (2 × 50 ml), the organics combined and then washed with water (50 ml) then with brine (50 ml), dried (MgSO 4 ), then concentrated to dryness. Purification of the residue via flash silica chromatography (0-15% methanol-dichloromethane) yielded the title compound as a pale orange solid (1.62 g; 5.66 mmol; 36%). ; 12.9 mmol; 20.0 equiv.), and the resulting solution was heated to reflux overnight with stirring. The reaction mixture was allowed to cool, then water was added (10 cm 3 ) and the mixture was stirred for a further 15 min. The resulting precipitate was then collected via filtration, yielding the title compound as an off-white powder (171 mg; 0.53 mmol; 82%). Compound 4 was synthesized in two steps from commercially available reagents, as follows.
6-Ethyl-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromene-2-carboxylic acid. A solution of 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone (0.5 g; 1.75 mmol; 1.0 equiv.) in pyridine (10 cm 3 ) was cooled to 0°C, then methyl chlorooxoacetate (1.14 cm 3 ; 7.00 mmol; 4.0 equiv.) was added dropwise with stirring. Dichloromethane (20 cm 3 ) was then added to the resulting slurry and poured onto HCl (1 M aq.; 30 cm 3 ). The organics were separated, then the aqueous layer was extracted with dichloromethane (2 × 30 3 ) and organics were combined, washed with brine (3 × 30 cm 3 ), dried (MgSO 4 ) and concentrated to dryness to give an orange residue. This was taken up in methanol (10 cm ) was added to the residue and heated to 65°C with stirring overnight. The resulting solution was allowed to cool and HCl (1 M aq.) was added until the solution reached pH 1 (pH paper). The resulting precipitate was collected via filtration and washed with a little water, then a little diethyl ether to give the title compound as an off-white powder (127 mg; 0.37 mmol; 21%). 119.2, 117.3, 116.9, 104.7, 19.30, 43.1, 32.1, 30.4 CCT018159 and compounds 1 and 2 were purchased from commercial vendors (CCT018159 from Tocris and compounds 1 and 2 from Enamine).
